Anlotinib in Advanced Solid Tumors With FGFR Alteration
This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.
Advanced Solid Tumor
DRUG: Anlotinib
Objective Response Rate(ORR), Evaluation of tumor burden based on RECIST criteria., up to 36 months
This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.